JP Morgan Chase
RLAY icon

JP Morgan Chase’s Relay Therapeutics RLAY Stock Holding History

JP Morgan Chase’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,000
Closed -$99K – 7269
2023
Q1 		$99K Buy
+6,000
New +$108K ﹤0.01% 5437

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

JP Morgan Chase's RLAY Position: Q2 2026 in Review

JP Morgan Chase increased its Relay Therapeutics (RLAY) stake by 24% in Q2 2026, buying an estimated $2.24M and bringing the position to 801,657 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2403.

JP Morgan Chase first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. The position peaked at $112M in Q3 2022. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • JP Morgan Chase held 801,657 shares of Relay Therapeutics worth $16M as of Q2 2026.
  • JP Morgan Chase bought 154,139 Relay Therapeutics shares in Q2 2026, an estimated $2.24M.
  • Relay Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2403 holding.
  • JP Morgan Chase first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Relay Therapeutics position peaked at $112M in Q3 2022.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.